A pproximately 1.8% of all pregnancies 1 are affected by chronic hypertension (cHTN) defined as hypertension detected before 20 weeks of gestation or predating pregnancy.
A pproximately 1.8% of all pregnancies 1 are affected by chronic hypertension (cHTN) defined as hypertension detected before 20 weeks of gestation or predating pregnancy. 2 The risk for significant maternal and fetal morbidity and death is increased in women with cHTN and is in part related to the severity of maternal hypertension. Although some women with preexisting hypertension experience a decrease in blood pressure (BP) during pregnancy, the risk for superimposed preeclampsia (SPE) [3] [4] [5] is increased 5-fold, which amplifies the risk of adverse outcomes. BP regulation during pregnancy is not fully understood. Vasodilation and lower BP may be caused by hormonally mediated increases in nitric oxide, accompanied by resistance to the vascular effects of angiotensin II. All components of the renin-angiotensin-aldosterone system (RAAS) are elevated beginning in early pregnancy, likely in response to vasodilation and lower BP. 6 These changes have been most often studied in normotensive women, with only few investigations in women with cHTN with or without SPE. [7] [8] [9] Although most studies report elevated plasma renin activity (PRA) and aldosterone in pregnancy, there is controversy about the factors that are responsible for these changes.
We previously studied 29 women with cHTN and reported that the RAAS is upregulated and that PRA and 24-hour urine aldosterone (Ualdo) are lower when SPE develops, 9 similar to what has been observed in normotensive women who develop PE. [10] [11] [12] We report here a larger study of the RAAS in 110 women with cHTN with and without preeclampsia and include measurements of BP, as well as serum and urine electrolytes, to further clarify the basis for the alterations in BP, PRA, and aldosterone in chronic hypertensive pregnancy.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Subjects
Clinical data, venous blood, and 24-hour urine were collected as part of the Chronic Hypertension in Pregnancy Study, a placebocontrolled, double-blinded, randomized trial of calcium for the prevention of SPE in women with preexisting cHTN performed at New York Presbyterian-Weill Cornell, the trial concluded in 2000. The study protocol was approved by the institutional review board at Weill-Cornell Medical College, and informed consent was obtained at the initial visit. 13, 14 Additional institutional review board approval was obtained for the analyses performed for this report. The data that support the findings of this study are available from the corresponding author on reasonable request. Eligible women were 18 to 45 years old who were 12 to 15 weeks pregnant at the time of screening and had cHTN, defined as a BP ≥140/90 mm Hg (on ≥2 separate measurements) or being on pharmacological therapy for cHTN before 20 weeks of gestation or preceding pregnancy. Women with white-coat hypertension based on normal home BP readings were not eligible. Women with a serum creatinine ≥1.2 mg/dL or a creatinine clearance <75 m/min, a history of calcium metabolism disorder, a diagnosis of secondary hypertension, a history of nephrolithiasis, or on chronic diuretic therapy were excluded.
Study Protocol
Study subjects were randomly allocated to treatment with either calcium carbonate (2 g daily) or placebo. The baseline study visit conducted at 12 to 15 weeks of gestation included an evaluation of medical history, weight, height, heart rate, and BP. Venous blood was collected for measurement of electrolytes and PRA, and 24-hour urine was obtained for measurement of creatinine, aldosterone, protein, sodium, and potassium. BP was measured according to the American Heart Association criteria 15 and was determined as the average of 3 consecutive measurements that were assessed in a seated position after a 5-minute rest period. All measurements were made by 1 observer.
Patients were followed every 4 weeks or more frequently if clinical condition warranted. Laboratory testing was performed at baseline, 20, 28, 36 weeks of gestation and at 6 weeks postpartum. The data characterizing BP, RAAS profiles, blood, and urine electrolytes have not been previously published.
Participants were treated with antihypertensive medications to maintain their BP at a goal of 140 to 150 mm Hg systolic and 90 to 100 mm Hg diastolic. 13 Treatment included methyldopa, labetalol, or long-acting nifedipine. Medication initiation and titration was managed by the principal investigator for the study.
Pregnancy outcomes (diagnoses) were ascertained after delivery by the primary investigator as SPE or No SPE after review of the participant's chart. There are no unanimously accepted criteria to define SPE. In accordance with The National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy 3 guidelines and our previous studies, 14 we diagnosed SPE after 20 weeks gestation when there was an increase in BP ≥30 mm Hg systolic and 15 mm Hg diastolic compared with baseline, in association with new-onset proteinuria (either 300 mg per 24 hours or ≥2+ by dipstick on ≥2 occasions). If proteinuria was present at baseline, SPE was diagnosed if there was doubling of urinary protein excretion after 20 weeks' gestation in association with a significant increase in BP. Women without increased proteinuria were diagnosed with SPE if BP was elevated and in association with elevated liver enzymes (2× baseline) and a low platelet count (<100 000/µL). 14 Blood for PRA was drawn into tripotassium ethylenediaminetetraacetic acid Vacutainer blood collection tubes (Becton-Dickinson, Rutherford, NJ) and processed at room temperature to avoid cryoactivation of prorenin. 16 Plasma was stored at −40°C and assayed within 2 days of collection by an enzymatic radioimmunoassay in which the angiotensin I generated at 37°C from endogenous angiotensinogen in the presence of converting enzyme and angiotensinase inhibitors was quantified by radioimmunoassay. Results are expressed as nanograms of angiotensin I per milliliter per hour. The interassay coefficient of variation for our in-house PRA assay was 7.6%.
Ualdo was measured after acid hydrolysis of the 3-oxo-conjugate. The aldosterone formed was then measured with Coat-a-Count aldosterone kit (Diagnostic Products, LA). 17 The assay was validated for use in pregnancy by showing that separation of aldosterone from other steroids by chromatography did not reduce the reported values. The Ualdo assay had an interassay variability of 12.8%. Twenty-fourhour Ualdo was measured rather than plasma aldosterone as it reflects the overall aldosterone production for the day while canceling out the minute-to-minute variations in plasma aldosterone that can be attributed to posture, recent salt intake, and circadian rhythm. 18 
Statistical Analysis
All of the statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). Continuous variables were summarized using basic descriptive statistics, such as means, SDs, medians, quartiles, minimums and maximums, and comparisons between groups were made using either the Student t test or Mann-Whitney test, as appropriate for 2-group comparisons and either ANOVA or Kruskal-Wallis test as appropriate, for multiple group comparisons. Categorical variables were compared using either the χ 2 or Fisher exact test where appropriate.
We examined the correlations between PRA and Ualdo to determine whether, within subjects, changes in PRA were associated with changes in Ualdo over time. We used the ANCOVA methods of Bland and Altman, 19 which allows for the computation of within-subjects correlations where the pairs of outcome variables are collected as repeated measurements. We adjusted for gestational age, 24-hour urine potassium, 24-hour urine sodium, serum potassium, and mean arterial pressure (MAP).
A mixed models approach to repeated measures ANOVA was used to determine whether there was a difference in levels of PRA between diagnosis group (SPE versus No SPE) and across gestational ages; the interaction of diagnosis group and gestational age was included in the model to examine whether the patterns of change in levels of PRA differed across visit weeks according to final diagnosis. A similar analysis was performed separately for Ualdo. Bonferroniadjusted pairwise comparisons were applied as necessary to adjust for multiple comparisons.
Data transformations were applied when the model assumptions were not met. The log transformation was found to be appropriate in the analysis for PRA, and therefore, all analysis was performed using the log-transformed values of PRA; however, results are reported in the original untransformed units for ease of interpretation. For Ualdo, no data transformations were found to be necessary.
Results

Study Participants
One hundred sixteen pregnancies were included in the Chronic Hypertension in Pregnancy Study. For this analysis, we excluded 6 pregnancies that were lost to follow-up and did not have documented delivery outcomes. An additional patient was excluded who was diagnosed with primary hyperaldosteronism, and another patient was excluded because of persistent nephrotic syndrome (which may indicate underlying chronic kidney disease). A total of 108 pregnancies were included in our analysis. The mean±SD age was 33±5.6 years, ranging from 20 to 47 years, 40% were black, and 43% (47/108) were primiparous. Thirty-two percent (19/60) of multiparous women had a history of SPE in a prior pregnancy.
Pregnancy Outcomes
Thirty-seven women (34%) developed SPE, whereas 71 did not. All women with SPE had a significant increase (30/15 mm Hg) in BP. 3 Serum uric acid and 24-hour urine protein excretion was significantly higher in the SPE group at weeks 28 and 36 of gestation (P<0.001; further detailed in Table S1 in the online-only Data Supplement). Eight out of 37 women diagnosed with SPE did not have proteinuric SPE, whereas 29 of 37 had proteinuric SPE. Women without proteinuric SPE were diagnosed on the basis of an abrupt increase in BP in association with other laboratory abnormalities (elevated liver enzymes, low platelets). Baseline characteristics of those with and without SPE were similar except for a higher prevalence of previous SPE in women who developed SPE in the current pregnancy (Table) . Forty-one women (38%) were on antihypertensive medication during the first trimester of pregnancy and 54 (50%) used antihypertensive medication during their pregnancy. At baseline, more women were on antihypertensives in the SPE group (17/37; 46.0%) compared with the No SPE group (24/71; 33.8% but this difference was not statistically significant P=0.30). Both SPE and No SPE groups also had similar office BPs at their initial visit. Among women who were on antihypertensives, those who later developed SPE were on a higher number of medications than women who did not develop SPE at baseline (P≤0.03). The analysis of antihypertensive medications use is presented in Table S2 . Women with SPE delivered earlier (gestational age at delivery, 34.5±5.0 versus 37.5±4.0 weeks; P<0.001). Women with SPE had lower birthweight infants (2435±885 versus 3034±745 g; P<0.001), and higher cesarean section rates (69% versus 41%; P=0.009) compared with those without SPE (Table S3 ).
Longitudinal Profiles of MAP, the RAAS, and Serum and Urine Electrolytes
MAP was significantly higher in women who developed SPE, starting at 20 weeks of gestation (P<0.001; Figure 1A ). MAP was not significantly different between the groups in early pregnancy and in the postpartum period.
The change in PRA throughout pregnancy differed in women with and without SPE (P=0.028). PRA increased from baseline to week 20 and was similar in both groups ( Figure 1B) . At week 28, PRA decreased in the SPE group, whereas it continued to increase in women without SPE. Thirty out of 34 patients had a PRA measured at 28 weeks at least 2 to 3 weeks before preeclampsia being diagnosed. PRA was significantly lower in women who developed SPE at week 28 (5.99±2.88 versus 6.22±3.00 ng/mL per hour; P<0.001) and at week 36 (5.71±3.23 versus 7.74±6.10 ng/mL per hour; P=0.002). PRA levels later decreased at the end of pregnancy in both groups. PRA was similar in both groups 6 weeks postpartum.
There was some heterogeneity in the longitudinal changes in PRA in women with and without SPE. In women without SPE, 39 of 61 had a significant increase in PRA from 20 to 28 weeks, whereas 21 of 61 had a small decrease and 1 had a stable PRA. In contrast, in the SPE group, more women had a decrease in PRA (17/31) and fewer had an increase.
Twenty-four-hour Ualdo levels appeared consistently higher in women who did not develop SPE compared with those who did and were parallel to each other throughout gestation. Ualdo increased throughout pregnancy in women with and without SPE and mixed model analysis demonstrated a significant time effect (P<0.0001) but no significant difference between final diagnosis groups (P<0.0599). The mixed model analysis also did not reveal a statistically significant difference in the pattern of change in Ualdo over time between the 2 groups (interaction effect P=0.30; Figure 1C ). Ualdo was higher at weeks 28 and 36 compared with week 12 (P<0.0001). Ualdo was also significantly higher at, each subsequent time point compared with the previous values (P<0.0001). When levels at specific time points were compared between women with and without SPE, Ualdo at 28 weeks was significantly lower in women with SPE compared with No SPE (59.6±49.9 versus 81.3±57.9 μg/d; P=0.039 by Mann-Whitney U). An additional mixed model analysis of both PRA and Ualdo was performed, adjusting for the use of β-blockers and methyldopa, and the results for both PRA and Ualdo remained unchanged, suggesting that the patterns of change in PRA and Ualdo were not affected by use of medications that may affect the RAAS (Table S2 ).
The ratio of Ualdo/PRA was similar in women with and without SPE throughout most of pregnancy and pairwise comparisons failed to demonstrate a significant difference between SPE and No SPE at the different time points in pregnancy. The Ualdo/PRA ratio was significantly higher in the SPE compared with the No SPE group only at the postpartum Plasma renin activity (PRA) and 24-hour urine aldosterone (U aldo) during pregnancy in women with chronic hypertension who develop superimposed preeclampsia (SPE) and who do not develop SPE. Mean arterial pressure (MAP) and renin-angiotensin-aldosterone system (RAAS) profiles were studied in 108 women with chronic hypertension in pregnancy. A, displays the mean MAP (in mm Hg) in women who develop SPE group in red and in women who do not develop SPE (No SPE group). B, The mean PRA (in ng/mL per hour) for the SPE group (in red) and for the No SPE group (in blue). C, The mean U aldo (in μg/d) for the SPE group (in red) and for the No SPE group (in blue). The 95% confidence interval is represented by error bars. A mixed models approach to repeated measures ANOVA was used to compare longitudinally logPRA and Ualdo across diagnostic groups. MAP was compared across diagnostic groups using Mann-Whitney U testing. Bonferroni-adjusted pairwise comparisons are applied so that P value <0.008 between both group is considered to be statistically significant and is denoted by an asterisk (*). P value <0.001 is denoted by (**).
visit (22.0 versus 12.7; P<0.02). Serum potassium, fractional excretion of potassium, 24-hour urine excretion of potassium and sodium were stable throughout pregnancy ( Figure 2 ) and were similar in SPE and No SPE (Table S1) .
We compared RAAS profiles in black and nonblack women (Figure 3) . The patterns of change in PRA and Ualdo were not significantly different between race groups (P<0.607), and the PRA levels did not differ significantly over time (P<0.456). Despite a similar pattern of change, we found that PRA was consistently lower throughout pregnancy in black women compared with other groups (white, Hispanic, and Asian; P<0.0001). Ualdo was also consistently lower in black women (P<0.0003). Levels increased throughout pregnancy with a similar pattern to what was found in the entire cohort.
Fetal outcomes are shown in Table S3 . There were 5 small for gestational age (with birthweight below the 10th percentile for gestational age) infants, all in the SPE group (Table S3) . The mean maternal PRA decreased in all 5 women from 20 to 28 weeks (mean decrease, 2.1 ng/mL per hour). The mean PRA was 4.19 and 2.04 ng/mL per hour, respectively, at 20 and 28 weeks and was lower than women without small for gestational age infants. This observation is consistent with previous reports that low PRA (unadjusted) is associated with poor fetal outcomes, including low birth weight. 20, 21 MAP was inversely related to both PRA (r=−0.23; P<0.0001) and Ualdo (r=−0.11; P=0.029). As expected, PRA and Ualdo were significantly and positively associated with each other (r=0.5327; P<0.0001) after adjusting for urine potassium, urine sodium, serum potassium, and MAP.
We performed a multivariable analysis to determine significant predictors of PRA and Ualdo, separately, during gestation (ie, excluding postpartum) while adjusting for diagnosis (SPE and No SPE), MAP, urine sodium, urine potassium, serum K, and PRA or Ualdo, respectively (Figure 4 ). Both Ualdo (P<0.0001) and nonblack race (P<0.0002) were positively associated with PRA. Gestational age (P<0.0001), PRA (P<0.0001), urine potassium (P<0.0001), and urine sodium (P<0.0005) were significant predictors of Ualdo excretion. For every unit (in ng/mL per hour) increase in PRA, there was a 2.41 μg/d increase in Ualdo.
Discussion
Striking alterations in the renin-angiotensin system in pregnancy are well documented; however, their significance remains controversial. The lower BP, apparent in early pregnancy, along with increased cardiac output, renal blood flow, and glomerular filtration rate 22 suggest to us that the basis for the stimulated RAAS in pregnancy is generalized vasodilation resulting in baroreceptor mediated increased maternal renal renin secretion. This study confirms our prior report 9 and shows that when BP increases in pregnant women with cHTN who develop SPE, either in the second or third trimester, PRA and Ualdo excretion both decrease, suggesting that primary stimulation of the RAAS is not the cause of preeclamptic hypertension. The high incidence of SPE reported in our Figure 3 . Renin-angiotensin-aldosterone system profiles in women with chronic hypertension in pregnancy. A, The mean plasma renin activity (PRA in ng/ mL per hour) in women from black racial background (in black) when compared with women from racial backgrounds other than black (in gray). The patterns of change in PRA are not statistically different; however, PRA levels are consistently lower in the black race group (P<0.0001) by mixed model analysis, which adjusts for multiple measurements and gestational age. B, The mean urine aldosterone (Ualdo; 24-h aldosterone urinary excretion in μg/d) for the other than black racial group (in gray) and for the black racial group (in black). Patterns of change in Ualdo are not statistically different; however, Ualdo levels are consistently lower in the black race group (P<0.0003) by mixed model analysis. The 95% confidence interval is represented by error bars.
study is attributed to a referral bias as our participants were all patients at a specialized hypertension center. Nevertheless, a similar suppression of the RAAS has also been described in women who were normotensive during most of their pregnancy and then develop preeclampsia. 8, 10, 11, 23, 24 The increases in BP in women with either preeclampsia or SPE have been attributed to endothelial dysfunction with decreases in vasodilatory factors, such as nitric oxide, prostacyclin, and VEGF (vascular endothelial growth factor), and increases in vasoconstrictors, such as endothelin. 25 Our finding that both PRA and Ualdo levels are suppressed when SPE develops is consistent with the notion that preeclamptic hypertension may also be associated with decreased sodium excretion and volume expansion. This mechanism of BP elevation may be similar to the hypertension observed in patients with glomerulonephritis and nephrotic syndrome. 26, 27 Evidence that both urinary plasminogen and plasmin levels are increased in women with preeclampsia, possibly resulting in activation of ENaC (epithelial sodium channel) [28] [29] [30] [31] is particularly intriguing and consistent with a role of excess sodium volume in preeclamptic hypertension. Surprisingly, plasma volume, which is difficult to accurately measure in women, has been reported to be decreased in women with preeclampsia and has been attributed to an increase in vascular permeability and increased interstitial volume. [32] [33] [34] However, the findings of increased atrial natriuretic factor and increased NT-proBNP (N-terminal pro-B-type natriuretic peptide) in preeclampsia 35 are more suggestive of an overfilled, rather than an underfilled circulation. Our study did not involve plasma volume monitoring or NT-proBNP measurement; however, the decrease in PRA seen in women with SPE is also consistent with an increased effective arterial blood volume status as perceived by the RAAS. Other studies have suggested additional, mechanisms for decreased RAAS profiles associated with preeclampsia, including impaired VEGF-mediated stimulation of aldosterone synthase because of increases in sFlt-1 (soluble fms-like tyrosine kinase 1). 36 VEGF blockade has also been reported to decrease renal renin secretion. 37 There is some disagreement on the basis for the changes in the RAAS in preeclampsia. Wu et al 38, 39 report a dissociation between renin and aldosterone when preeclampsia develops. 23, 35 Some suggest that lower renin and aldosterone is a primary event in women with preeclampsia and that this causes sodium leaking 24 and decreased plasma volume. We suggest that based on our findings, the RAAS is responding appropriately and physiologically to primary increased vasoconstriction and sodium reabsorption. It is worth pointing out that, despite the stimulation of the RAAS in pregnancy, and the suppression with preeclampsia, serum potassium levels were remarkably constant suggesting that a primary disturbance in the RAAS is not the cause of preeclamptic hypertension. Furthermore, our findings of a constant Ualdo/PRA ratio, a consistent positive association between PRA and Ualdo, and an inverse relationship between BP and both PRA and Ualdo are consistent with this notion.
Our study has limitations. The collection of specimens in this study was protocol driven, and in some women, blood and urine were obtained from 2 to 4 weeks before the development of preeclampsia, whereas in others, specimens were obtained closer to the time of diagnosis.
A B Figure 4 . Multivariable modeling of plasma renin activity (PRA) and 24-h urine aldosterone (Ualdo) excretion in pregnancies affected by chronic hypertension.
A, A multivariable model was performed using PRA as the dependent the variable and the following covariates: 24-h Ualdo, urine potassium (UK), urine sodium (UNa), serum potassium (serum K), mean arterial pressure (MAP), gestational age, black race (when compared with other racial groups), and superimposed preeclampsia (SPE). The variables in the green circles were associated with an increase in PRA, whereas the red circles were associated with a decrease in PRA. B, A multivariable model was performed using 24-h Ualdo as the dependent the variable and the following covariates: PRA, UK, UNa, serum K, MAP, gestational age, black race (when compared with other racial groups), and SPE. The variables in green circles were associated with an increase in Ualdo, whereas those in red circles were associated with a decrease in Ualdo. Circles and arrows drawn with a solid line represent statistically significant effects (P value <0.05), whereas circles and arrows drawn with broken lines represent effects that are not statistically significant (P value ≥0.05). The numbers represent the numeric effect of the variable on PRA (A) or Ualdo (B). For example, an increase in 1 μg/d in Ualdo is associated with a 0.02 ng/mL per hour increase in PRA.
Although our subjects were not on a fixed sodium intake, 24-hour urine excretion was similar in women with and without SPE, suggesting that differences in dietary sodium were not the main cause of the differences in RAAS profiles. Antihypertensive medication, such as β-blockers, may suppress PRA; however, our analysis of medication suggests that differential use of β-blockers was not responsible for the suppressed PRA in women with SPE.
In conclusion, longitudinal profiling of the RAAS in women with cHTN demonstrates elevated PRA and Ualdo beginning in the first trimester, and remaining elevated unless SPE develops. These alterations are associated with normal levels of serum potassium and stable urinary electrolyte excretion, consistent with the notion that the stimulated RAAS in pregnancy is an appropriate physiological response to early pregnancy vasodilation, lower BP, and possible transient underfilling of the circulation. Finally, the basis for the lower levels of PRA and Ualdo in black compared with nonblack pregnant women are consistent with reports in nonpregnant individuals in whom lower PRA and increased prevalence of salt sensitivity are observed 40 but remain poorly understood.
Perspectives
Women with preexisting or cHTN are at risk for considerable morbidity during pregnancy because of accelerating hypertension and the development of preeclampsia. Our study addresses the longitudinal alterations in the RAAS and serum and urine electrolytes during pregnancy in women with cHTN with and without SPE and sheds light on the pathogenesis of hypertension in pregnancy. Whether the suppressed RAAS in women with SPE is because of primary renal vasoconstriction, or primary renal sodium retention mediated by plasmin induced stimulation of ENaC, [28] [29] [30] [31] is worthy of further study. Our data suggest that a second-trimester decrease in PRA (compared with first trimester) in a woman with rising BP and signs of preeclampsia may provide additional support for the diagnosis of SPE. Our study is the first report, to our knowledge, of lower PRA and Ualdo throughout pregnancy in black women compared with other racial groups.
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